Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 21 Apr 2018 Status changed from not yet recruiting to recruiting.
- 06 Feb 2018 Planned End Date changed from 1 Nov 2022 to 2 Apr 2022.
- 06 Feb 2018 Planned primary completion date changed from 1 Nov 2020 to 2 Apr 2021.